Ui-Soon Khoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8234676/publications.pdf Version: 2024-02-01

	101543	114465
4,662	36	63
citations	h-index	g-index
133	133	7397
docs citations	times ranked	citing authors
	4,662 citations 133 docs citations	4,662 36 citations h-index 133 133 docs citations 133 times ranked

#	Article	IF	CITATIONS
1	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16369-16374.	7.1	375
2	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene, 2016, 35, 990-1002.	5.9	167
3	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis, 2013, 34, 1476-1486.	2.8	147
4	Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer. PLoS Genetics, 2012, 8, e1002532.	3.5	137
5	Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nature Genetics, 2014, 46, 886-890.	21.4	135
6	FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene, 2012, 31, 1845-1858.	5.9	131
7	Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nature Genetics, 2006, 38, 38-46.	21.4	127
8	DC-SIGN and L-SIGN: the SIGNs for infection. Journal of Molecular Medicine, 2008, 86, 861-874.	3.9	127
9	Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer, 2001, 91, 949-956.	4.1	121
10	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene, 2014, 33, 4144-4155.	5.9	109
11	OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene, 2016, 35, 1433-1444.	5.9	108
12	Identification of a Functional Genetic Variant at 16q12.1 for Breast Cancer Risk: Results from the Asia Breast Cancer Consortium. PLoS Genetics, 2010, 6, e1001002.	3.5	107
13	A Germline Mutation (A339V) in Thyroid Transcription Factor-1 (TITF-1/NKX2.1) in Patients With Multinodular Goiter and Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2009, 101, 162-175.	6.3	105
14	Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Research, 2002, 62, 4151-6.	0.9	98
15	Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Human Molecular Genetics, 2011, 20, 4991-4999.	2.9	92
16	Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer. PLoS ONE, 2010, 5, e12293.	2.5	90
17	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Human Molecular Genetics, 2013, 22, 2539-2550.	2.9	86
18	Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecologic Oncology, 2004, 93, 435-440.	1.4	80

#	Article	IF	CITATIONS
19	Liquid-based cytology and conventional cervical smears. Cancer, 2003, 99, 331-335.	4.1	75
20	Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene, 1999, 18, 4643-4646.	5.9	74
21	Replication and Functional Genomic Analyses of the Breast Cancer Susceptibility Locus at 6q25.1 Generalize Its Importance in Women of Chinese, Japanese, and European Ancestry. Cancer Research, 2011, 71, 1344-1355.	0.9	71
22	Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. International Journal of Cancer, 2008, 123, 296-302.	5.1	66
23	Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: A founder mutation of BRCA1 identified in the Chinese population. Human Mutation, 2002, 19, 307-308.	2.5	65
24	Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology, 2001, 38, 243-249.	2.9	63
25	Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization. Modern Pathology, 2004, 17, 40-48.	5.5	60
26	A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. Journal of Experimental Medicine, 2007, 204, 2529-2536.	8.5	56
27	Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology, 2005, 46, 307-313.	2.9	54
28	Promoter Methylation and Differential Expression of π-Class Glutathione S-Transferase in Endometrial Carcinoma. Journal of Molecular Diagnostics, 2005, 7, 8-16.	2.8	51
29	Dual-utility NLS drives RNF169-dependent DNA damage responses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2872-E2881.	7.1	51
30	Primary peritoneal malignant mixed M�llerian tumors. Cancer, 2001, 91, 1052-1060.	4.1	48
31	Prognostic significance of minichromosome maintenance proteins in breast cancer. American Journal of Cancer Research, 2015, 5, 52-71.	1.4	47
32	Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole. Cancer, 2004, 100, 1411-1417.	4.1	46
33	Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis, 2006, 27, 1502-1506.	2.8	46
34	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nature Communications, 2020, 11, 1217.	12.8	46
35	Epigenetic and genetic alterations of p33 ING1b in ovarian cancer. Carcinogenesis, 2005, 26, 855-863.	2.8	45
36	Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snailâ€induced epithelial–mesenchymal transition. Journal of Pathology, 2011, 224, 78-89.	4.5	45

#	Article	IF	CITATIONS
37	Microsatellite instability in mitochondrial genome of common female cancers. International Journal of Gynecological Cancer, 2006, 16, 259-266.	2.5	42
38	p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression. Journal of Clinical Pathology, 1998, 51, 159-162.	2.0	37
39	CD209 (DC-SIGN) â^'336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Human Immunology, 2010, 71, 702-707.	2.4	37
40	Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Human Mutation, 2000, 16, 88-89.	2.5	36
41	Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology, 2003, 43, 485-490.	2.9	36
42	Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome. Journal of Infectious Diseases, 2007, 196, 271-280.	4.0	33
43	Coexisting Epithelioid Trophoblastic Tumor and Choriocarcinoma of the Uterus Following a Chemoresistant Hydatidiform Mole. Archives of Pathology and Laboratory Medicine, 2003, 127, e291-e293.	2.5	33
44	FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene, 2015, 34, 5012-5024.	5.9	32
45	Significance of the Myxovirus Resistance A (MxA) Gene â^'123C>A Singleâ€Nucleotide Polymorphism in Suppressed Interferon β Induction of Severe Acute Respiratory Syndrome Coronavirus Infection. Journal of Infectious Diseases, 2010, 201, 1899-1908.	4.0	31
46	Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. International Journal of Gynecological Cancer, 1999, 9, 123-130.	2.5	30
47	Malignant placental site trophoblastic tumor. Cancer, 2002, 94, 2288-2294.	4.1	30
48	Mixed low grade and high grade endometrial stromal sarcoma of uterus: differences on immunohistochemistry and chromosome in situ hybridisation Journal of Clinical Pathology, 1996, 49, 604-607.	2.0	29
49	SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of <i>NCOR2/SMRT</i> That Is Associated with Tamoxifen Resistance and Control of <i>ERα</i> Transcriptional Activity. Cancer Research, 2013, 73, 246-255.	0.9	29
50	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment. Oncogenesis, 2016, 5, e252-e252.	4.9	29
51	BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis, 2016, 5, e214-e214.	4.9	28
52	Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. Journal of Medical Genetics, 2008, 46, 32-39.	3.2	27
53	Collision of Endometrioid Carcinoma and Stromal Sarcoma of the Uterus. International Journal of Gynecological Pathology, 1999, 18, 77-81.	1.4	26
54	Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome. Cancer, 2005, 103, 268-276.	4.1	26

#	Article	IF	CITATIONS
55	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. Oncogenesis, 2015, 4, e167-e167.	4.9	26
56	Malignant melanoma of the female genital tract A report of nine cases in the Chinese of Hong Kong. Pathology, 1991, 23, 312-317.	0.6	24
57	Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer. Current Molecular Medicine, 2013, 13, 410-416.	1.3	24
58	Fibro-osseous pseudotumor of the digits: report of a case with immunohistochemical and ultrastructural studies. Pathology, 1993, 25, 193-196.	0.6	23
59	BQ323636.1, a Novel Splice Variant to <i>NCOR</i> 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3681-3691.	7.0	23
60	Cervical and Peritoneal Fluid Cytology of Uterine Sarcomas. Acta Cytologica, 2002, 46, 465-469.	1.3	22
61	Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. Gynecologic Oncology, 2004, 92, 866-872.	1.4	22
62	Subcutaneous Panniculitislike T-Cell Lymphoma Appearing as a Breast Mass. Journal of Ultrasound in Medicine, 2005, 24, 1453-1460.	1.7	22
63	Single Nucleotide Polymorphism of Pi-Class Glutathione S-Transferase and Susceptibility to Endometrial Carcinoma. Clinical Cancer Research, 2005, 11, 2981-2985.	7.0	22
64	Pathway Analyses Identify <i>TGFBR2</i> as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1176-1184.	2.5	22
65	Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer. Cancers, 2021, 13, 1511.	3.7	22
66	Ovarian Mature Cystic Teratoma With Malignant Transformation An Interphase Cytogenetic Study. International Journal of Gynecological Pathology, 1998, 17, 351-357.	1.4	20
67	Pseudomyxoma peritonei - a heterogenous disease. International Journal of Gynecology and Obstetrics, 1998, 62, 173-182.	2.3	19
68	Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. Journal of Clinical Pathology, 2004, 57, 721-727.	2.0	19
69	Intraâ€abdominal desmoplastic small roundâ€cell tumour. Histopathology, 1992, 20, 531-534.	2.9	18
70	Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer. Oncogene, 2020, 39, 3206-3217.	5.9	18
71	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. Biomolecules, 2022, 12, 72.	4.0	18
72	Atypical squamous cells of undetermined significance on cervical smears. Cancer, 2004, 102, 74-80.	4.1	17

#	Article	IF	CITATIONS
73	Role of Serial Tumor Markers in the Surveillance for Recurrence in Endometrial Cancer. Cancer Detection and Prevention, 1999, 23, 397-400.	2.1	16
74	Fine Needle Aspiration Cytology of Myxopapillary Ependymoma. Acta Cytologica, 1998, 42, 1022-1026.	1.3	15
75	Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Familial Cancer, 2008, 7, 125-133.	1.9	15
76	ld helix-loop-helix proteins are differentially expressed in gestational trophoblastic disease. Histopathology, 2005, 47, 303-309.	2.9	14
77	The Role of Pea3 Group Transcription Factors in Esophageal Squamous Cell Carcinoma. American Journal of Pathology, 2011, 179, 992-1003.	3.8	14
78	Sudden death associated with bloodless aortic dissection. Forensic Science International, 1993, 59, 149-155.	2.2	13
79	ls immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas?. Human Pathology, 1997, 28, 91-94.	2.0	13
80	Applications of localized image processing techniques in wireless sensor networks. , 2003, , .		13
81	Detection of mitochondrial DNA mutations in gestational trophoblastic disease. Human Mutation, 2003, 22, 177-177.	2.5	12
82	Challenging and Unusual Cases. Journal of Clinical Oncology, 2003, 21, 1417-1418.	1.6	12
83	Primary peritoneal malignant mixed Müllerian tumors. A clinicopathologic, immunohistochemical, and genetic study. Cancer, 2001, 91, 1052-60.	4.1	12
84	The expression of cathepsin D, oestrogen receptor and progestogen receptor in hydatidiform mole?an immunohistochemical study. Histopathology, 1995, 27, 341-347.	2.9	11
85	Expression of p53 in recurrent nodal metastasis from nasopharyngeal carcinoma (NPC). European Journal of Surgical Oncology, 1997, 23, 415-418.	1.0	11
86	The first batch of graduates of a new medical curriculum in Asia: how their teachers see them. Medical Education, 2004, 38, 980-986.	2.1	11
87	Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. Cancers, 2022, 14, 1251.	3.7	11
88	KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer. Clinical and Translational Medicine, 2021, 11, e554.	4.0	10
89	Reply to "Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection― Nature Genetics, 2007, 39, 694-696.	21.4	9
90	Cholestatic liver cell adenoma in a child with hirsutism and elevated serum levels of cortisol and ACTH. Histopathology, 1994, 25, 586-588.	2.9	8

#	Article	IF	CITATIONS
91	c-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions. International Journal of Gynecological Pathology, 2004, 23, 145-150.	1.4	8
92	Rapid death from thrombotic thrombocytopaenic purpura following caesarean section. Forensic Science International, 1992, 54, 75-80.	2.2	7
93	Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. Journal of Clinical Pathology, 2006, 59, 845-850.	2.0	7
94	CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes. FEBS Letters, 2007, 581, 4668-4674.	2.8	7
95	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. Cancers, 2020, 12, 533.	3.7	7
96	Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong. Hong Kong Medical Journal, 2016, 22, 144-151.	0.1	7
97	Repurposing hyperpolarizationâ€activated cyclic nucleotideâ€gated channels as a novel therapy for breast cancer. Clinical and Translational Medicine, 2021, 11, e578.	4.0	7
98	Epstein-Barr virus in carcinoma of the vulva Journal of Clinical Pathology, 1993, 46, 849-851.	2.0	6
99	Re: Population-Based Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. Journal of the National Cancer Institute, 2002, 94, 1581-1582.	6.3	6
100	Localization of hRad9 in breast cancer. BMC Cancer, 2008, 8, 196.	2.6	6
101	Necrolytic Migratory Erythema in Glucagonoma Syndrome. Journal of Dermatology, 1992, 19, 369-374.	1.2	5
102	A retroperitoneal immature teratoma with rhabdomyoblastic and nephroblastic differentiation. Pathology, 2006, 38, 364-367.	0.6	5
103	Regarding "Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients― Breast Cancer Research and Treatment, 2012, 131, 351-352.	2.5	5
104	PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model. Cancer Letters, 2018, 430, 67-78.	7.2	5
105	The utility of ancillary tests in the diagnosis of jaundice. Medical Informatics = Medecine Et Informatique, 1988, 13, 93-104.	0.8	4
106	Gynaecological cancers in genetically susceptible women: new thoughts on tubal pathology. Diagnostic Histopathology, 2009, 15, 545-553.	0.4	4
107	Nuclear Localization Marker of FOXO3a: Can it be Used to Predict Doxorubicin Response?. Frontiers in Oncology, 2013, 3, 149.	2.8	4
108	A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review. Case Reports in Oncology, 2021, 14, 90-97.	0.7	4

#	Article	IF	CITATIONS
109	Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life, 2022, 12, 93.	2.4	4
110	What factors facilitate interprofessional collaboration outcomes in interprofessional education? A multi-level perspective. Nurse Education Today, 2022, 114, 105393.	3.3	4
111	Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization. Modern Pathology, 2004, 17, 40-48.	5.5	4
112	A transitional course from high school to medical school in a new medical curriculum in Asia: how do the students see it?*. Medical Teacher, 2003, 25, 89-91.	1.8	3
113	Primary peritoneal malignant mixed Müllerian tumors. Cancer, 2001, 91, 1052-1060.	4.1	3
114	Biologic Markers in Breast Cancer: An Update. Journal of Histotechnology, 1998, 21, 317-325.	0.5	2
115	To IPAS or not to IPAS? Examining the construct validity of the Interprofessional Attitudes Scale in Hong Kong. Journal of Interprofessional Care, 2022, 36, 127-134.	1.7	2
116	Abstract 2040: Identification of microRNAs associated with tamoxifen resistance in breast cancer. Cancer Research, 2010, 70, 2040-2040.	0.9	2
117	What characterize high and low achieving teams in Interprofessional education: A self-determination theory perspective. Nurse Education Today, 2022, 112, 105321.	3.3	2
118	Gastric carcinoma in young Hong Kong Chinese. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 343-346.	2.8	1
119	Cytogenetic study of malignant ovarian germ cell tumors by chromosome in situ hybridization. International Journal of Gynecological Cancer, 1998, 8, 222-232.	2.5	1
120	Palpable asymmetrical thickening of the breast: aclinical, radiological and pathological study. British Journal of Radiology, 2001, 74, 402-406.	2.2	1
121	Innovative use of technologies to enhance the teaching of pathology. Pathology, 2014, 46, S31.	0.6	1
122	Response from authors. Forensic Science International, 1992, 57, 87-88.	2.2	0
123	Collecting duct carcinoma presenting as a bleeding complicated renal cyst. Annals of the College of Surgeons of Hong Kong, 2000, 4, 167-168.	0.0	Ο
124	Clinicopathologic features of primary intraosseous carcinoma in situ arising from odontogenic keratocyst: A case report and literature review. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2021, 33, 354-357.	0.3	0
125	Using Risk Stratification to Optimize Mammography Screening in Chinese Women. JNCI Cancer Spectrum, 2021, 5, pkab060.	2.9	0
126	Abstract 3156: eIF4E in human breast cancer and its role in regulating translation of splice variants of breast cancer genes. , 2010, , .		0

#	Article	IF	CITATIONS
127	Abstract 3334: The role of nuclear HER3 in breast cancer resistance. , 2014, , .		0
128	Abstract 4761: Translational regulation by eIF4E and its contribution to tamoxifen resistance in breast cancer. , 2016, , .		0
129	Abstract 5903: The molecular mechanism for producing BQ323636.1 in Tamoxifen resistance breast cancer cells. , 2018, , .		0